Given the unique challenges in pediatric care, including variations in age, weight, and developmental stages, the choice of administration devices and the accuracy of dosing are vital considerations.

At this point, where the epidemiology and diagnostic tools and conditions are different in children versus adults, it then also becomes clear that the antifungal dosing itself is quite unique in ...

The guidelines noted appropriate vancomycin dosing to be dependent on factors ... Dosing guidance for specific populations (such as pediatrics, morbid obesity and patients with renal dysfunction ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) ...

“Dosing adolescents is the first step in evaluating the safety and PK of nomlabofusp in pediatric patients with FA. We continue to enroll adolescents in our first cohort. This cohort will be ...

Larimar Therapeutics has initiated dosing for adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for nomlabofusp, a potential treatment for Friedreich’s ataxia.